Three sensitivity analyses were performed. First, a second matching step was performed in which two controls were selected for each case, where possible using a nearest neighbor and caliper metric. Controls needed to have propensity scores within 0.1 of the case to be selected. Thirty-eight of the 39 cases had at least one control using this method and for 36 cases two controls could be selected. The average difference between case and control propensity adjuvant RT was 0.008 (range 0.00003-0.095).
A second sensitivity analysis was performed to guard against immortal time bias. In order to mitigate the possibility of this effect, cases known not to have undergone adjuvant RT have been screened for suitable follow-up without a recurrence (local or regional recurrence, metastatic failure, and/or death) to ensure that if adjuvant RT had been prescribed as part of the multi-modality treatment regimen, that it would have been initiated. Three months was selected as the mandatory follow-up time. One to one matching was carried out and all 39 cases were matched to a control. A third sensitivity analysis was performed to account for stage migration seen in control patients that presented to the University of Michigan with more advanced disease. Patients that underwent adjuvant radiation were matched one to one with control group patients who did not receive adjuvant radiation, and who had the same stage at diagnosis as compared to stage at University of Michigan presentation.
The search data supports a literature review project on lifestyle therapies for the management of atrial fibrillation. The data included in the dataset are the reproducible search strategies (in docx) and the exported results of all citations from all databases (txt and ris files). These searches and exported result files contain all citations originating from the database searches that were considered for inclusion.
Abdul-Aziz AA, Altawil M, Lyon A, MacEachern M, Richardson CR, Rubenfire M, Pelosi F Jr, Jackson EA. Lifestyle Therapy for the Management of Atrial Fibrillation. Am J Cardiol. 2018 May 1;121(9):1112-1117. doi: 10.1016/j.amjcard.2018.01.023. PubMed PMID: 29650239. https://www.ncbi.nlm.nih.gov/pubmed/29650239
The research adheres to PRISMA-HARM recommendations for systematic reviews. The reproducible search strategies for all databases, the citation export files from all databases, and the eligibility screening decisions are included in the dataset.
This data and scripts are meant to test and show seizure differentiation based on bifurcation theory. A zip file is included which contains real and simulated seizure waveforms, Matlab scripts, and metadata. The matlab scripts allow for visual review validation and objective feature analysis. The file “README.txt” provides more detail about each individual file within the zip file. and Data citation: Crisp, D.N., Saggio, M.L., Scott, J., Stacey, W.C., Nakatani, M., Gliske, S.F., Lin, J. (2019). Epidynamics: Navigating the map of seizure dynamics - Code & Data [Data set]. University of Michigan Deep Blue Data Repository. https://doi.org/10.7302/ejhy-5h41
The data and the scripts are to show that seizure onset dynamics and evoked responses change over the progression of epileptogenesis defined in this intrahippocampal tetanus toxin rat model. All tests explored in this study can be repeated with the data and scripts included in this repository. and Dataset citation: Crisp, D.N., Cheung, W., Gliske, S.V., Lai, A., Freestone, D.R., Grayden, D.B., Cook, MJ., Stacey, W.C. (2019). Epileptogenesis modulates spontaneous and responsive brain state dynamics [Data set]. University of Michigan Deep Blue Data Repository. https://doi.org/10.7302/r6vg-9658
SPSS is required to access processed dataset in .sav format. Model output is provided as a word document, and Qualtrics survey instrument is included as PDF and .docx, where .docx version contains survey logic and question numbers.
Iyengar, R., Winkels, J., Smith, C. M., Meka, A. P., MD, Porath, J. D., MD, & Meurer, W. J., MD, MS. (2019, January 21). The Effect of Financial Incentives on Patient Decisions to Undergo Low-Value Head CT Scans. https://doi.org/10.31219/osf.io/4mdfw
Internally administered targeted radionuclide therapy (TRT) with radio-labelled targeting molecules that deliver cytotoxic radiation to tumor has been used successfully to treat multiple cancers. Lu-177, used increasingly in TRT, emits both beta particles that deliver the therapeutic effect. FDA recently approved a fixed activity (4 cycles of 7.4 GBq/cycle as in NETTER -1) administered every 8 weeks. With the patient studies under this treatment, we collected CT images and corresponding volume of interest (organs, lesions) contours.
We used data collected from participants of the Early Life Exposures in Mexico to ENvironmental Toxicants (ELEMENT) study, which consists of three sequentially-enrolled birth cohorts of pregnant women. Research protocols of this study were approved by the Institutional Review Board at University of Michigan and the Mexico National Institute of Public Health. We obtained informed consent from mothers and informed assent from children prior to enrollment.
The main goal of this research was to identify potential molecular pathways that contribute to memory dysregulation and decline that persists long after illness or inflammation. We have previously established a subchronic immune challenge model that results in memory impairments months after the inflammatory challenge. This project aimed to determine whether memory impairments were accompanied by transcriptional dysregulation in memory related brain region (the hippocampus).
These data show the differential gene expression as log2fold change (and p-value) in males and females 3 months after immune challenge (Supp Tables 1 and 2); after a subsequent immune challenge (Supp Tables 3 and 4); the differential regulation of genes in males and females (Supp Table 5); genes differentially expressed in the hippocampus of males and females at baseline (Supp Table 6) and the differential regulation of those genes in males and females after immune challenge (Supp Tables 7,8).